Coloplast delivered organic growth of 7% in the first nine months of the 2014/15 financial year, increasing revenue measured in Danish kroner by 12% to DKK 10,288 million.
EBIT before special items was up by 8% to DKK 3,286 million, with the EBIT margin before special items at 32%, versus 33% in 9M 2013/14.
Coloplast continues to deliver growth in all business areas and in all markets. Organic sales growth rates by business area in the 9M period were as follows: Ostomy Care 6%, Continence Care 7%, Urology Care 5% and Wound & Skin Care 9%. In the reporting period, Coloplast grew its European business by 5%, Other Developed Markets by 5% and Emerging Markets by 20%.
“We're presenting a financial performance in line with the revised guidance we announced in June. Organic growth at 7% both for the third quarter and for the nine-month period is a satisfactory performance,” said Coloplast CEO Lars Rasmussen.
“We're continuing our string of growth in line with or ahead of the market in all four business areas, and we've maintained solid momentum across our overall business. Our Wound & Skin Care business continues to deliver solid growth rates, and in the important European region, a major market like France is performing strongly,” said Mr Rasmussen, and he continued: “Also, new products like SenSura Mio and Biatain Silicone have become significant drivers of our growth.”
Based on the Q3 interim report, Coloplast continues to expect FY 2014/15 organic revenue growth of about 7% and of about 12% in DKK. The EBIT margin forecast remains at about 32%, both at constant exchange rates and in DKK.
For further information, click here to read the 9M Interim Report.
PRESS CONTACT
Simon Mehl Augustesen
Senior Manager, Media Relations
+45 4911 3488
dksia@coloplast.com
INVESTOR RELATIONS
Ian Christensen
Vice President, Investor Relations
+45 4911 1301
dkisec@coloplast.com
